Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.

Two and four treatments of 5 mmol kg-1 of buthionine sulfoximine (BSO) at an interval of 12 h depleted the glutathione (GSH) content in NFSa tumours of C3H/He mice, respectively, to 24.0 and 1.78 percent of the untreated controls. BSO pre-treatments every 12 h enhanced the cytotoxicity of cyclophosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, K., Komuro, C., Tsutsui, K., Shibamoto, Y., Nishidai, T., Takahashi, M., Abe, M., Shrieve, D. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001553/
https://www.ncbi.nlm.nih.gov/pubmed/3801271
_version_ 1782135628264112128
author Ono, K.
Komuro, C.
Tsutsui, K.
Shibamoto, Y.
Nishidai, T.
Takahashi, M.
Abe, M.
Shrieve, D. C.
author_facet Ono, K.
Komuro, C.
Tsutsui, K.
Shibamoto, Y.
Nishidai, T.
Takahashi, M.
Abe, M.
Shrieve, D. C.
author_sort Ono, K.
collection PubMed
description Two and four treatments of 5 mmol kg-1 of buthionine sulfoximine (BSO) at an interval of 12 h depleted the glutathione (GSH) content in NFSa tumours of C3H/He mice, respectively, to 24.0 and 1.78 percent of the untreated controls. BSO pre-treatments every 12 h enhanced the cytotoxicity of cyclophosphamide (CYC) towards artificial lung micrometastases of NFSa tumours giving enhancement ratios (ERs) ranging from 1.75 to 1.83 and from 2.41 to 2.73, for two and four BSO pretreatments respectively. Large ERs were obtained at low CYC doses (high cell survival). Four BSO pre-treatments at an interval of 12 h did not increase the cytotoxicity of CYC to bone marrow stem cells. Our results suggest a clinical applicability of the combination of BSO and CYC.
format Text
id pubmed-2001553
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20015532009-09-10 Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow. Ono, K. Komuro, C. Tsutsui, K. Shibamoto, Y. Nishidai, T. Takahashi, M. Abe, M. Shrieve, D. C. Br J Cancer Research Article Two and four treatments of 5 mmol kg-1 of buthionine sulfoximine (BSO) at an interval of 12 h depleted the glutathione (GSH) content in NFSa tumours of C3H/He mice, respectively, to 24.0 and 1.78 percent of the untreated controls. BSO pre-treatments every 12 h enhanced the cytotoxicity of cyclophosphamide (CYC) towards artificial lung micrometastases of NFSa tumours giving enhancement ratios (ERs) ranging from 1.75 to 1.83 and from 2.41 to 2.73, for two and four BSO pretreatments respectively. Large ERs were obtained at low CYC doses (high cell survival). Four BSO pre-treatments at an interval of 12 h did not increase the cytotoxicity of CYC to bone marrow stem cells. Our results suggest a clinical applicability of the combination of BSO and CYC. Nature Publishing Group 1986-11 /pmc/articles/PMC2001553/ /pubmed/3801271 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ono, K.
Komuro, C.
Tsutsui, K.
Shibamoto, Y.
Nishidai, T.
Takahashi, M.
Abe, M.
Shrieve, D. C.
Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
title Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
title_full Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
title_fullStr Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
title_full_unstemmed Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
title_short Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
title_sort combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001553/
https://www.ncbi.nlm.nih.gov/pubmed/3801271
work_keys_str_mv AT onok combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT komuroc combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT tsutsuik combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT shibamotoy combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT nishidait combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT takahashim combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT abem combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow
AT shrievedc combinedeffectofbuthioninesulfoximineandcyclophosphamideuponmurinetumoursandbonemarrow

Ejemplares similares